Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Other Non-Current Assets (2023 - 2025)

Historic Other Non-Current Assets for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $1.3 million.

  • Tonix Pharmaceuticals Holding's Other Non-Current Assets rose 3659.31% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 3659.31%. This contributed to the annual value of $951000.0 for FY2024, which is 1576.62% down from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's Other Non-Current Assets stood at $1.3 million, which was up 3659.31% from $931000.0 recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's 5-year Other Non-Current Assets high stood at $1.3 million for Q3 2025, and its period low was $292000.0 during Q2 2023.
  • Moreover, its 3-year median value for Other Non-Current Assets was $951000.0 (2024), whereas its average is $892727.3.
  • Examining YoY changes over the last 5 years, Tonix Pharmaceuticals Holding's Other Non-Current Assets showed a top increase of 22910.96% in 2024 and a maximum decrease of 1576.62% in 2024.
  • Tonix Pharmaceuticals Holding's Other Non-Current Assets (Quarter) stood at $1.1 million in 2023, then fell by 15.77% to $951000.0 in 2024, then skyrocketed by 36.59% to $1.3 million in 2025.
  • Its Other Non-Current Assets stands at $1.3 million for Q3 2025, versus $931000.0 for Q2 2025 and $910000.0 for Q1 2025.